Product
Supplier
Encyclopedia
Inquiry
Phosphate -1310746-10-1 buy - large image1
Phosphate -1310746-10-1 buy - image1

Phosphate -1310746-10-1

6 Inquiries

Unit Price:

$890-899/MT FOB

Get Latest Price
CAS No.:

1310746-10-1

Grade:

Pharmaceutical Grade

Content:

99%

Port:

CHINA

Packaging:

1G

Price valid (until):

2026-08-14

Company Type:
Trader
Location:
United States
Qualification:
Main Products:

peptides

  • Product Description

  • Seller Information

  • Inquiry History

  • Description


      Product Detail  


    Pls input...

    Items Specifications
    NVP BGJ398 phosphate
    Description: IC50 Value: 0.9 nM (FGFR1); 1.4 nM (FGFR2); 1 nM (FGFR2) [1] NVP-BGJ398 is a novel selective, pan-specific FGFR inhibitor currently in Phase I clinical trials for cancer therapy. in vitro: NVP-BGJ398 is a novel and selective fibroblast growth factor receptor (FGFR) inhibitor. NVP-BGJ398 inhibit FGFR1, FGFR2, FGFR3 with IC50 of 0.9 nM, 1.4 nM and 1 nM. NVP-BGJ398 inhibited FGFR1, FGFR2, and FGFR3 with single digit nmol/L IC50 in biochemical and cellular autophosphorylation assays and FGFR4 with 38- to 60-fold lower potency. NVP-BGJ398 significantly inhibits proliferation of cancer cell lines bearing FGF/FGFR genetic alterations across various cancer types.Among the 35 cell lines selected from the high-throughput assays, 28 were confirmed as sensitive to NVP-BGJ398 with IC50s ranging from 0.001 to 500 nM. Cancer cell lines harboring FGF19 copy number gain at the 11q13 amplicon are sensitive to NVP-BGJ398 only when concomitant expression of beta-klotho occurs [1]. Cell lines with activating FGFR2 mutations (S252W, N550K) were more sensitive to dovitinib or NVP-BGJ398 when compared with their FGFR2 wild-type counterparts (P = 0.073 and P = 0.021, respectively). Both agents inhibited FGFR2 signaling, induced cell-cycle arrest, and significantly increased apoptosis in FGFR2-mutant lines. In vitro, dovitinib and NVP-BGJ398 were both potent at inhibiting cell growth of FGFR2-mutant endometrial cancer cells, but the activity of dovitinib was less restricted to FGFR2-mutant lines when compared with NVP-BGJ398 [2]. in vivo: In tumor tissues from primary tumor model GAM033 treated with 15 mg/kg NVP-BGJ398, NVP-BGJ398 shows inhibition to FGFR and ERK1/2 [1].NVP-BGJ398 significantly inhibited the growth of FGFR2-mutated endometrial cancer xenograft models [2]. Toxicity: N/A Clinical trial: Phase 1


    Basic Info
    Product Name:

    Infigratinib phosphate

    CAS No.:

    1310746-10-1

  • Seller Information
    Business Type:

    Trader

    Main Products:

    peptides

    Location:

    126 AUTUMN ROAD ,LAKEWOOD NEW JERSEY

    Payment Terms:

    TT against copy of documents,100% TT in advance

    Total Annual Revenue:

    $10 million-$25 million

    Total Employees:

    51-100

    Year of Establishment:

    2023

    Certifications:

    certifacate for peptieds

  • Inquiry History
    6 Inquiries
    Country Product Purchase Quantity Date Posted
    United States

    NVP BGJ398 Phosphate

    1 KG Jul 15, 2026
    United States

    NVP BGJ398 phosphate

    3 G Jul 15, 2026
    United States

    Infigratinib

    9 G Jul 18, 2026
    United States

    Infigratinib phosphate powder

    6 G Jun 9, 2026
    United States

    NVP-BGJ398 phosphate

    18 G Jul 14, 2026
    United States

    NVP BGJ398 phosphate

    4 G Mar 11, 2026
    Post an enquiry for this product
pic ×

Scan the QR Code to Share

All products displayed on this website are only for non-medical purposes such as industrial applications or scientific research, and cannot be used for clinical diagnosis or treatment of humans or animals. They are not medicinal or edible.

According to relevant laws and regulations and the regulations of this website, units or individuals who purchase hazardous materials should obtain valid qualifications and qualification conditions.

The information shown above is provided by the enterprise itself, and the authenticity, accuracy and legitimacy of the content are the responsibility of the publishing company. ECHEMI does not bear any guarantee responsibility for this. Please be aware that risks in internet transactions objectively exist.

Feedback & Suggestions
Send Message

Thank you for your feedback. If you require further assistance, please contact us by email at info@echemi.com or call us at +86-532-55729510.